US · Healthcare · Biotechnology
EPS came in at 1.01 against a street estimate of 0.68 — a beat of 48.5%.
Analysts rate Corcept Therapeutics Incorporated a buy (4 buy, 0 hold, 1 sell out of 5) with an average price target of $141.00.
CONFIDENT Q2 revenue $256M (+32% YoY) driven by Cushing's (Korlym $209M) and oncology launch (Lifyorli $48M first quarter). Raised FY26 guidance to $1.1–1.2B. Relacorilant resubmission accepted; PDUFA Dec 17, 2026. Q2 2026 Call did not segment revenue by geography. Analysts pressed Lifyorli channel build vs. organic uptake, Korlym pharmacy-transition contribution, and inventory dynamics. Management emphasized organic demand, record patient/prescriber adds, and minimal inventory in specialty pharmacy channel (~100% Cushing's, ~30% oncology). 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 11.50% |
| Ingalls & Snyder LLC | 7.34% |
| Renaissance Technologies Corp | 4.87% |
| Vanguard Portfolio Management, LLC | 4.67% |
| Vanguard Capital Management, LLC | 3.86% |
| Parallel Advisors, LLC | 3.67% |
| FMR Inc | 3.09% |
| State Street Corp | 3.03% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 product revenue was $340,472 thousand, up from $207,638 thousand in the third quarter of 2025. • Nine-month 20 | 2026-11-03 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $340.5 million, up from $256.1 million in the second quarter of 2026 and up 64 percent from the sam | 2026-11-03 |
| Board / officer change · Q3 2026 CORCEPT THERAPEUTICS INCORPORATED - 8-K SUMMARY HEADLINE NUMBERS • Sean Maduck, President of Corcept Endocrinology, resigned effective October 1, 20 | 2026-09-23 |
| Quarterly report · Q2 2026 CORCEPT THERAPEUTICS INCORPORATED Form 10-Q Summary for Retail Investors Period Ended: June 30, 2026 --- HEADLINE NUMBERS • Product Revenue (Q2 202 | 2026-07-29 |
| Results announced · Q3 2026 CORCEPT THERAPEUTICS – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $256.1 million – 32% increase vs. Q2 2025 ($194.4 million) • Ko | 2026-07-29 |
| Company announcement · Q2 2026 CORCEPT THERAPEUTICS INC. (CORT) - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company resubmitted a New Drug Application (NDA) to the U.S. Food and | 2026-06-17 |
| Company announcement · Q2 2026 CORCEPT THERAPEUTICS INCORPORATED – 8-K SUMMARY HEADLINE NUMBERS • Company: Corcept Therapeutics Incorporated (Nasdaq: CORT) • Filing Date: May 19, | 2026-06-03 |
| Board / officer change · Q2 2026 CORCEPT THERAPEUTICS INCORPORATED - FORM 8-K SUMMARY HEADLINE NUMBERS • Total shares entitled to vote at Annual Meeting: 107,356,686 • Total shares | 2026-05-28 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Corcept Therapeutics Incorporated — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.